[Angioedema and anaphylaxis, a family story]

Camille Martinet; Nadia Gherri; Léon Laborde; Cédric Gil-Jardine; Anthony Chauvin; Hugues Lefort

doi:10.1016/j.revinf.2022.05.010

[Angioedema and anaphylaxis, a family story]

Rev Infirm. 2022 Jun-Jul;71(282):27-29. doi: 10.1016/j.revinf.2022.05.010. Epub 2022 May 26.

[Article in French]

Authors

Camille Martinet¹, Nadia Gherri², Léon Laborde³, Cédric Gil-Jardine⁴, Anthony Chauvin⁵, Hugues Lefort²

Affiliations

¹ Structure des urgences, Hôpital d'instruction des armées Laveran, 13384 Marseille, France. Electronic address: [email protected].
² Structure des urgences, Hôpital d'instruction des armées Laveran, 13384 Marseille, France.
³ Antenne médicale, 17(e) régiment du génie parachutiste (RGP), 42 avenue du 10(e)-Dragon, 82000 Montauban, France.
⁴ Structure des urgences, CHU Pellegrin, rue de la Pelouse-de-Douet, 33000 Bordeaux, France.
⁵ Structure des urgences, CHU Lariboisière, 2 rue Ambroise-Paré, 75010 Paris, France.

PMID: 36150835
DOI: 10.1016/j.revinf.2022.05.010

Abstract

Non-allergic angioedema has a worrying morbidity. Clinical examination is central, as C1-esterase inhibitor deficiency will not be documented in the acute phase. In the case of anaphylaxis that does not respond to adrenaline, an early diagnosis can optimise referral of the patient to a reference healthcare establishment for a specific therapeutic protocol (icatibant, C1 inhibitor) recently updated by recommendations.

Keywords: C1-INH; angioedema; angioneurotic; angioneurotique; angiœdème; bradykinin; bradykinine; hereditary; histamine; héréditaire; icatibant.

MeSH terms

Anaphylaxis* / diagnosis
Anaphylaxis* / therapy
Angioedema* / drug therapy
Angioedema* / therapy
Angioedemas, Hereditary* / diagnosis
Angioedemas, Hereditary* / drug therapy
Epinephrine / therapeutic use
Esterases / therapeutic use
Humans

Substances

Esterases
Epinephrine